Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Neutral Inonotus obliquus polysaccharide (IOP-W): Structural characterization and p53/MAPK-mediated apoptotic activity against pancreatic Cancer unveiled through multi-omics.

Created on 26 Sep 2026

Authors

Xinze Liu, Guinan Zhu, Lin Wang, Lin Feng, Xin Jin, Jiaqi Zhao, Hongmei Yang, Guangzhe Li, Renbo Tan, Lei Wang, Xilin Wan

Published in

International journal of biological macromolecules. Pages 154618. Sep 25, 2026. Epub Sep 25, 2026.

Abstract

Inonotus obliquus is a medicinal fungus growing on birch bark. A neutral polysaccharide (IOP-W, Mw = 8.222 kDa) was isolated from its crude polysaccharides via sequential DEAE DE-52 cellulose column and Sephadex G-200 gel filtration column chromatography. IOP-W, composed primarily of galactose, glucose, and mannose, was structurally characterized by UV-Vis, FT-IR, GC-MS, and NMR as a glucan containing →4)-α-D-Glcp-(1→, →6)-β-D-Glcp-(1→, →3)-β-D-Glcp-(1→, →4,6)-α-D-Glcp-(1→, terminal α-D-Glcp, and β-D-Glcp reducing end. AFM confirmed its aggregated spherical morphology. IOP-W exerted antitumor activity against MIA PaCa-2 cells by modulating apoptosis and migration. Metabolomics revealed effects on amino acids, alkaloids, lipids, and nucleotides involving 20 pathways, while transcriptomic KEGG analysis showed regulation of MAPK, TNF, and p53 signaling. In vivo investigations employing small animal MRI technology have validated that tumor growth is significantly suppressed in animal models, accompanied by elevated spleen index and improved physiological parameters. Western blotting and immunohistochemistry revealed altered expression of Parp-1, p53, Bax/Bcl-2, p-ERK1/2, p-JNK1, NF-κB, vimentin, and MMP-9. These findings indicate that IOP-W inhibits pancreatic cancer via the p53/MAPK pathway, highlighting its potential as a fungal polysaccharide-based therapeutic candidate.

PMID:
42790566
Bibliographic data and abstract were imported from PubMed on 26 Sep 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 7
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement